My research goals lie mainly in the field of cancer metabolism and cancer therapeutics. Interest in cancer metabolism is keen because metabolic re-programming has recently emerged as a new hallmark of cancer. Along with that our understanding of new metabolic pathways and interconnected signaling cascades resulting in metabolic alterations has also been enhanced. These molecular insights now offer the possibility of developing novel anticancer treatments targeting tumor dependence on altered metabolic pathways. Given that interesting platform, I intend to focus mainly on the interplay of Glucose metabolism and associated signaling to decipher particular molecular alteration(s) that resulted in metabolic reprogramming and target that alternation for a successful therapeutics.
B.Sc: Microbiology, Calcutta University.
M.Sc: Microbiology, Calcutta University.
PhD: Biotechnology, CSIR-Indian Institute of Chemical Biology.
Post-doctoral Research: Department of Laboratory Medicine and Pathology, Mayo Clinic, MN, USA.
Fellowships and Awards
2003: National Scholarship by Ministry of Human Resource Development, Government of India.
2003: Surendranath College Prize for securing 2nd highest Marks in Microbiology in Surendranath College, Kolkata.
2005: Qualified National Eligibility Test (NET-CSIR) in Life Science, jointly organized by UGC and CSIR.
2013: Mayo Clinic Ovarian Cancer SPORE fellowship awarded by the National Institute of Health (NIH), USA.
2019: Early Career Research Award in Life Science by Science and Engineering Research Board (SERB -DST), Government of India.
From the very first day in the school curriculum when ‘Cell’ has been introduced to me, to till date, ‘Cell’ has always fascinated me. It fascinates me how a tiny cell knows that ‘when to do and what to do’ and the coordination and delegation of work among the organelles. In parallel, I have developed an interest towards the biology of microbes during my graduation and post-graduation. Particularly, how microbes associate with the host and how their interactions alter and regulate cellular functions. And with that, I have two avenues open in front of me for my research endeavor. During the summer project of M.Sc curricula in Bose Institute on cancer immunomodulation and therapeutics, I again inclined towards cell biology and developed a strong connection towards cell biology of cancer and its therapeutics.
After completion of my Masters's, I joined CSIR-IICB as CSIR-JRF. My doctoral work involves the identification of new molecular targets and the development of new herbal drugs in the context of cancer. Later, I joined the Department of Laboratory Medicine and Pathology at Mayo Clinic, MN, USA as a Post-doctoral Research Associate where I have worked with Dr. Viji Shridhar on altered cancer metabolism in Ovarian Cancer.
In April 2019, I joined Presidency University.
Interest in cancer metabolism is keen because metabolic re-programming has recently emerged as a new hallmark of cancer. Along with that our understanding of new technology, discoveries of new metabolic pathways, and our deeper mechanistic understanding of the interconnected signaling cascades have also been enhanced. These molecular insights now offer the possibility of developing novel anticancer treatments targeting tumor dependence on altered metabolic pathways. With this understanding and training in cancer biology, currently, I am trying to establish my laboratory here in the Presidency University with the DST-SERB funding and intend to work independently as well as in a collaborative approach.
I have been teaching for more than 15 years now and the syllabus covered are General Microbiology, Microbial Physiology, Microbial Genetics, Cell biology, cellular signaling, and Immunology.
After joining Presidency University, I have taught Microbial Biotechnology for one year (Sem I and Sem II).
Research Scholars:
1. Ms. Mehnaz Ahmed
2. Ms. Sramana Bhowmick
3. Ms. Tannishtha Biswas
Dissertation Students:
2024
1. Ms. Oishika Gangopadhyay
2. Ms. Pratiksha Ghosh
2022-23
1. Ms. Upasana Mandal
2. Mr. Tathagata Chatterjee
2021-22
1. Ms. Chetana Mandal
2. Mr. Pritam Debnath
2020-21
1. Ms. Sramana Bhowmick
2. Ms. Noiranjana Dasgupta
Peer reviewed Publications (In reverse chronology)
- Ahmed M, Biswas T, Mondal S*. The strategic involvement of IRS in cancer progression. Biochem Biophys Res Commun. 2023 Nov 5;680:141-160. Epub 2023 Sep 16 (IF: 3.1). *Corresponding author
- Bhowmick S, Biswas T, Ahmed M, Roy D, Mondal S*. Caveolin-1 and lipids: Association and their dualism in oncogenic regulation. Biochim Biophys Acta Rev Cancer. 2023 Oct 15;1878(6):189002 (IF: 11.2). *Corresponding author
- Pal S, Bhowmick S, Sharma A, Sierra-Fonseca JA, Mondal S, Afolabi F, Roy D. Lymphatic vasculature in ovarian cancer. Biochim Biophys Acta Rev Cancer. 2023 Sep;1878(5):188950. doi: 10.1016/j.bbcan.2023.188950. Epub 2023 Jul 5 (IF: 11.2).
- Mondal S, Roy D, Sarkar Bhattacharya S, Jin L, Jung D, Zhang S, Kalogera E, Staub J, Wang Y, Xuyang W, Khurana A, Chien J, Telang S, Chesney J, Tapolsky G, Petras D, Shridhar V. Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers. Int J Cancer. 2019;144(1):178-189 (IF: 7.360).
- Kalogera E, Roy D, Khurana A, Mondal S, Weaver AL, He X, Dowdy SC, Shridhar V. Quinacrine in endometrial cancer: Repurposing an old antimalarial drug. Gynecol Oncol 2017; 146(1):187-195. (IF: 5.3)
- Roy D, Mondal S, Khurana A, Jung DB, Hoffmann R, He X, Kalogera E, Dierks T, Hammond E, Dredge K, Shridhar V. Loss of HSulf-1: The Missing Link between Autophagy and Lipid Droplets in Ovarian Cancer. Sci Rep. 2017; 7;7:41977. (IF: 4.525)
- Mondal S, Roy D, Camacho-Pereira J, Khurana A, Chini E, Yang L, Baddour J, Stilles K, Padmabandu S, Leung S, Kalloger S, Gilks B, Lowe V, Dierks T, Hammond E, Dredge K, Nagrath D, Shridhar V. HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer. Oncotarget. 2015; 20;6(32):33705-19 (IF: 5.168)
- Khurana A, Roy D, Kalogera E, Mondal S, Wen X, He X, Dowdy S, Shridhar V. Quinacrine promotes autophagic cell death and chemosensitivity in ovarian cancer and attenuates tumor growth. Oncotarget. 2015; 3;6(34):36354-69.
- Winterhoff B, Freyer L, Hammond E, Giri S, Mondal S, Roy D, Teoman A, Mullany SA, Hoffmann R, von Bismarck A, Chien J, Block MS, Millward M, Bampton D, Dredge K, Shridhar V. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. Eur J Cancer 2015;51(7):879-92 (IF: 8.4).
- Roy D*, Mondal S*, Wang C, He X et al. Loss of HSulf-1 promotes altered lipid metabolism in ovarian cancer. Cancer Metab. 2014;18;2:13.). *Equal contribution. (IF: 5.1).
Book Chapters:
- Biswas, T., Ahmed, M., Mondal, S. (2024). Rejuvenating the Potential of Antimicrobials Via Targeted Therapy of Efflux Pumps. Medicinal Plants and Antimicrobial Therapies. Springer, Singapore. https://doi.org/10.1007/978-981-99-7261-6_4
Presidency University Students Corner